@entity171 are used in oncology as a means of decreasing complications due to bone metastases, in association with anticancer treatment, especially in @entity1 with @entity0 , @entity263 and @entity1582 . Little is known about the effects of @entity171 on bone metastases from other @entity5 and in particular from @entity5 for which no effective treatment is available. We conducted a randomized, double-blind placebo-controlled trial of oral @entity19160 in @entity1 with bone metastases from @entity5 poorly responsive to chemotherapy, with the aims of evaluating the effects of this drug on symptoms control and bone metastases evolution. Sixty-six @entity1 with poorly responsive @entity5 such as @entity1149 ( @entity1149 ), @entity150 , @entity1820 , @entity703 , @entity320 and @entity189 of unknown origin entered the study. @entity1 were randomized to receive either @entity19160 1,600 mg/day for one year or identical placebo-containing tablets. Various parameters such as Karnofsky performance status, @entity158 score (measured by a @entity227 ) and analgesic requirement were recorded at monthly intervals. Of the 66 @entity1 enrolled, 9 were observed for one month or less; 7 were followed for two months; only 50 @entity1 were followed for more than 2 months and could be adequately evaluated. At 3 months both @entity19160 and placebo-treated @entity1 had a decrease in Karnofsky performance status, with the decrease being more evident in the placebo group. Mean @entity158 scores showed an increase of @entity158 in @entity1 receiving placebo and a decrease of @entity158 in @entity1 receiving @entity19160 , although the difference failed to be statistically significant. Analgesics requirement increased in both groups, but significantly more in @entity1 receiving placebo (p = 0.042), in whom increase in opioid requirements was particularly evident. @entity137 was low, with occasional gastroenteric discomfort in both groups. The main problem of this study was the difficulty in recruiting an adequate number of @entity1 and following them for a sufficient period of time: general conditions rapidly deteriorated in many @entity1 , and approximately 25% of the 66 enrolled were not considered evaluable; few @entity1 survived for the length of the study, one year. This might partly account for the lack of significance of some of the parameters under study. With these limits, oral @entity19160 demonstrated some efficacy in symptom control and in reducing the need for analgesics.

A double blind randomized study of oral XXXX in the treatment of bone metastases from @entity5 poorly responsive to chemotherapy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual-analogue scale'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity171 :: ('MESH:D004164', 'Chemical') :: ['bisphosphonates', 'Bisphosphonates'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity189 :: ('MESH:D002277', 'Disease') :: ['metastatic carcinoma'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['myeloma'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer'] @entity1820 :: ('MESH:D005770', 'Disease') :: ['gastrointestinal cancers'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity19160 :: ('MESH:D004002', 'Chemical') :: ['clodronate'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma'] @entity703 :: ('MESH:D007680', 'Disease') :: ['kidney cancer']
@entity19160 :: (MESH:D004002,Chemical) :: ['clodronate']
